Opioid Antagonism in Hypogonadotropic Hypogonadism
Launched by STEPHANIE B. SEMINARA, MD · Jul 15, 2021
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Assignment: Each study subject will serve as their own control.
Delivery of Interventions:
* Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories.
* During the study, the subjects will undergo the following:
* Period 1: Undergo q10 min blood sampling for up to 12 hours
* Period 2: Undergo q10 min blood sampling for up to 12 hours
* Receive a naloxone bolus followed by a naloxone infusion
Gender
ALL
Eligibility criteria
- • Inclusion
- • Age 18-75 years
- • Confirmed diagnosis of hypogonadotropic hypogonadism
- • Genetic sequencing data available
- • All medical conditions stable and well controlled
- • If applicable, willing to use birth control methods (as approved by a study medical professional) during protocol participation
- • Normal blood pressure (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg)
- • Negative urine drug screening panel
- • Hemoglobin
- • Women: no less than 0.5 gm/dL below the lower limit of the reference range for normal women
- • Men on adequate testosterone replacement therapy: normal male reference range
- • Men off testosterone replacement therapy: no lower than 0.5 gm/dL below the lower limit of the reference range for normal women
- • For women, negative serum hCG pregnancy test
- • Exclusion
- • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
- • Current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis and, if applicable, unwilling to complete an appropriate washout for that particular medication and its method of administration
- • Current or recent use of a medication that affects the opioid pathway
- • Active illicit drug use
- • Excessive alcohol consumption (\> 10 drinks/week)
- • For women, pregnant or breastfeeding
About Stephanie B. Seminara, Md
Dr. Stephanie B. Seminara is a distinguished clinical trial sponsor renowned for her expertise in endocrinology, particularly in reproductive health and hormonal disorders. With a robust background in clinical research and a commitment to advancing medical knowledge, Dr. Seminara leads innovative studies aimed at improving therapeutic outcomes for patients with complex endocrine conditions. Her collaborative approach fosters partnerships with leading research institutions, ensuring the highest standards of ethical practice and scientific rigor in all clinical trials. Through her leadership, Dr. Seminara is dedicated to translating research findings into actionable treatments that enhance patient care and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Stephanie Seminara, MD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials